Short Interest in XORTX Therapeutics Inc. (NASDAQ:XRTX) Increases By 79.0%

XORTX Therapeutics Inc. (NASDAQ:XRTXGet Free Report) was the recipient of a significant increase in short interest in April. As of April 30th, there was short interest totaling 79,644 shares, an increase of 79.0% from the April 15th total of 44,502 shares. Based on an average daily trading volume, of 6,498,507 shares, the days-to-cover ratio is presently 0.0 days. Approximately 6.1% of the company’s shares are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of XORTX Therapeutics in a research report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Check Out Our Latest Stock Report on XORTX Therapeutics

XORTX Therapeutics Stock Performance

Shares of XORTX Therapeutics stock opened at $2.59 on Monday. XORTX Therapeutics has a one year low of $1.73 and a one year high of $7.05. The company has a market cap of $4.01 million, a price-to-earnings ratio of -0.86 and a beta of 0.80. The business’s 50 day moving average price is $2.32 and its 200 day moving average price is $2.60.

XORTX Therapeutics (NASDAQ:XRTXGet Free Report) last posted its earnings results on Thursday, February 26th. The technology company reported ($0.45) EPS for the quarter.

Institutional Investors Weigh In On XORTX Therapeutics

A hedge fund recently raised its stake in XORTX Therapeutics stock. Citadel Advisors LLC raised its holdings in XORTX Therapeutics Inc. (NASDAQ:XRTXFree Report) by 124.4% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 86,326 shares of the technology company’s stock after purchasing an additional 47,858 shares during the quarter. Citadel Advisors LLC owned 1.24% of XORTX Therapeutics worth $70,000 as of its most recent SEC filing. 0.23% of the stock is owned by hedge funds and other institutional investors.

About XORTX Therapeutics

(Get Free Report)

Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers.

Recommended Stories

Receive News & Ratings for XORTX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XORTX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.